| __timestamp | MiMedx Group, Inc. | Regeneron Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 12665000 | 205018000 |
| Thursday, January 1, 2015 | 20202000 | 392709000 |
| Friday, January 1, 2016 | 32407000 | 299694000 |
| Sunday, January 1, 2017 | 35219000 | 397061000 |
| Monday, January 1, 2018 | 36386000 | 434100000 |
| Tuesday, January 1, 2019 | 43081000 | 782200000 |
| Wednesday, January 1, 2020 | 39330000 | 1119900000 |
| Friday, January 1, 2021 | 43283000 | 2437500000 |
| Saturday, January 1, 2022 | 48316000 | 1560400000 |
| Sunday, January 1, 2023 | 54634000 | 1815800000 |
| Monday, January 1, 2024 | 1970500000 |
Unleashing the power of data
In the ever-evolving landscape of biotechnology, understanding the cost of revenue is crucial for assessing a company's financial health. Over the past decade, Regeneron Pharmaceuticals, Inc. and MiMedx Group, Inc. have showcased contrasting trajectories in their cost of revenue.
From 2014 to 2023, Regeneron Pharmaceuticals experienced a staggering 785% increase in its cost of revenue, peaking at approximately $1.82 billion in 2023. This growth reflects the company's aggressive expansion and investment in cutting-edge research and development.
Conversely, MiMedx Group's cost of revenue grew by 331% over the same period, reaching around $54.6 million in 2023. While smaller in scale, this growth indicates a steady commitment to innovation and market presence.
These trends highlight the dynamic nature of the biotech industry, where strategic investments can lead to significant financial shifts.
Comparing Cost of Revenue Efficiency: Sanofi vs MiMedx Group, Inc.
Comparing Cost of Revenue Efficiency: Regeneron Pharmaceuticals, Inc. vs Intra-Cellular Therapies, Inc.
Cost of Revenue Comparison: Regeneron Pharmaceuticals, Inc. vs Incyte Corporation
Cost of Revenue Trends: Regeneron Pharmaceuticals, Inc. vs Lantheus Holdings, Inc.
Regeneron Pharmaceuticals, Inc. vs Veracyte, Inc.: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Regeneron Pharmaceuticals, Inc. and Perrigo Company plc's Expenses
Cost of Revenue Trends: Regeneron Pharmaceuticals, Inc. vs ACADIA Pharmaceuticals Inc.
Cost Insights: Breaking Down Regeneron Pharmaceuticals, Inc. and Iovance Biotherapeutics, Inc.'s Expenses
Regeneron Pharmaceuticals, Inc. vs Xencor, Inc.: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Xenon Pharmaceuticals Inc. vs MiMedx Group, Inc.
Geron Corporation vs MiMedx Group, Inc.: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Travere Therapeutics, Inc. and MiMedx Group, Inc.'s Expenses